Amneal Pharmaceuticals, Inc.
AMRX
$17.25
$0.201.17%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 796.20M | 722.52M | 814.32M | 784.51M | 724.51M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 796.20M | 722.52M | 814.32M | 784.51M | 724.51M |
| Cost of Revenue | 463.78M | 403.95M | 518.54M | 490.19M | 440.27M |
| Gross Profit | 332.42M | 318.57M | 295.78M | 294.32M | 284.24M |
| SG&A Expenses | 148.72M | 138.86M | 146.48M | 137.82M | 124.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.30M | -64.00K | -1.00K | -117.00K | -- |
| Total Operating Expenses | 650.22M | 581.13M | 699.82M | 691.24M | 612.50M |
| Operating Income | 145.98M | 141.39M | 114.50M | 93.27M | 112.01M |
| Income Before Tax | 70.99M | 80.18M | 55.24M | -5.22M | 51.71M |
| Income Tax Expenses | 1.38M | 2.18M | 5.66M | -23.36M | 16.10M |
| Earnings from Continuing Operations | 69.61M | 78.00M | 49.57M | 18.13M | 35.61M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -11.95M | -15.74M | -14.50M | -15.76M | -13.19M |
| Net Income | 57.66M | 62.26M | 35.08M | 2.37M | 22.42M |
| EBIT | 145.98M | 141.39M | 114.50M | 93.27M | 112.01M |
| EBITDA | 193.78M | 184.58M | 163.73M | 147.34M | 172.12M |
| EPS Basic | 0.18 | 0.20 | 0.11 | 0.01 | 0.07 |
| Normalized Basic EPS | 0.13 | 0.11 | 0.07 | 0.05 | 0.06 |
| EPS Diluted | 0.18 | 0.19 | 0.11 | 0.01 | 0.07 |
| Normalized Diluted EPS | 0.13 | 0.11 | 0.07 | 0.05 | 0.06 |
| Average Basic Shares Outstanding | 319.20M | 316.02M | 314.46M | 314.17M | 313.74M |
| Average Diluted Shares Outstanding | 328.10M | 328.93M | 328.09M | 324.75M | 322.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |